Table 3 Multivariate analysis. Hazard ratios (HR) are given for PTCy with rATG being the comparator.

From: GVHD prophylaxis in matched related stem cell transplantation: Why post-transplant cyclophosphamide can be recommended a study by the EBMT transplant complications working party

 

HR (95% CI)

p-value

Relapse incidence

0.78 (0.66 to 0.92)

0.003

Non-relapse mortality

1.22 (0.95 to 1.57)

0.12

Overall survival

0.99 (0.85 to 1.16)

0.92

Progression-free survival

0.89 (0.78 to 1.03)

0.11

GVHD-free and Relapse-free survival

0.94 (0.82 to 1.07)

0.32

Acute GVHD-II/IV

1.10 (0.88 to 1.37)

0.39

Acute GVHD-III/IV

1.02 (0.74 to 1.39)

0.93

Chronic GVHD

1.01 (0.83 to 1.23)

0.90

Extensive chronic GVHD

0.97 (0.72 to 1.31)

0.85

  1. All known potential risk factors, and variables differing significantly across the groups were included in the multivariate models: patient age at transplant, year of transplant, patient and donor gender, donor to patient CMV combination, Disease Risk Index (DRI), Karnofsky Performance Status (KPS), any level of total body irradiation (TBI), conditioning intensity (RIC vs. MAC). Center effect was considered by introducing a random effect or ‘frailty’ into all models.
Back to article page